Published in Neuropsychiatr Dis Treat on May 20, 2009
Bapineuzumab. Expert Opin Biol Ther (2010) 1.12
Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Expert Opin Emerg Drugs (2012) 0.97
New treatments for chronic prostatitis/chronic pelvic pain syndrome. Nat Rev Urol (2010) 0.87
Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. Future Med Chem (2012) 0.84
Alzheimer's disease and age-related memory decline (preclinical). Pharmacol Biochem Behav (2011) 0.83
Pharmacokinetics of cotinine in rats: a potential therapeutic agent for disorders of cognitive function. Pharmacol Rep (2014) 0.77
Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease. Am J Pathol (2009) 0.75
Current advances in transdermal delivery of drugs for Alzheimer's disease. Indian J Pharmacol (2017) 0.75
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology (1994) 21.65
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med (2003) 6.79
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA (2004) 6.74
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 5.94
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med (2008) 4.03
NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol (2006) 3.61
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol (2006) 2.62
Memantine for dementia. Cochrane Database Syst Rev (2006) 2.52
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology (2007) 2.39
Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement (2007) 2.18
NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol (2008) 2.13
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry (2008) 2.12
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res (2008) 1.84
Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry (1999) 1.74
Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology (2004) 1.65
Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord (2008) 1.60
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry (2006) 1.57
The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 1.53
Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain. Eur J Health Econ (2006) 1.49
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology (2006) 1.47
Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord (2007) 1.35
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess (2006) 1.30
Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother (2007) 1.18
A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord (2007) 1.17
Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics (2003) 1.12
Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord (2006) 1.11
Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr (2007) 1.10
Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 1.09
Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 1.04
Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis (2008) 1.03
THE ADAMANTYL GROUP IN MEDICINAL AGENTS. I. HYPOGLYCEMIC N-ARYLSULFONYL-N' -ADAMANTYLUREAS. J Med Chem (1963) 1.01
Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging (2004) 1.00
Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther (2006) 0.99
Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. J Alzheimers Dis (2008) 0.96
Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord (2006) 0.94
Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf (2008) 0.92
From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. J Alzheimers Dis (2006) 0.90
Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review. Neuropsychiatr Dis Treat (2008) 0.88
Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. J Neurol (2007) 0.87
Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry (2007) 0.86
A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry (2006) 0.86
Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis. Pharmacoeconomics (2005) 0.86
Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland. Clin Drug Investig (2004) 0.85
Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin (2007) 0.85
Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother (2004) 0.85
Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology (2008) 0.83
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry (2007) 0.82
Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol (1998) 0.81
Outcome measures in Alzheimer's disease: do they go far enough? Dement Geriatr Cogn Disord (2000) 0.80
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin Drug Investig (2008) 0.80
Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol (2005) 0.80
Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry (2004) 0.80
Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry (1986) 0.80
Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord (2007) 0.80
Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother (2005) 0.79
A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs Aging (2006) 0.76